Recent numbers from the World Health Organization (WHO) demonstrate the importance of malaria in the global scenario. In the 2013 World Malaria Report, the number of malaria cases exceeded 200 million, with 627,000 deaths ([@B38]). These numbers have been fluctuating over recent decades, but in most endemic areas, no real possibility of elimination is expected in the next few years without envisioning new tools.

For reducing malaria transmission (i.e., malaria control), a successful programme should focus on several aspects, including early diagnosis, vector control and the use of effective antimalarial drugs. However, these strategies need to be emphasised in the elimination scenario ([@B33]). Moreover, searching for each individual case of malaria is a priority in the context of achieving zero reported cases ([@B34]). In this context, tools such as mass drug administration (MDA) and mass screening and treatment (MSAT) should be considered. However, other than unpublished experiences of individual malaria control programmes, there is a lack of robust evidence supporting the efficacy of specific tools for malaria control and elimination.

Gametocyte stages are non-replicating forms that are responsible for the transmission of the malaria parasite to the mosquito vector. In contrast to other species of *Plasmodium*, *Plasmodium falciparum* gametocytes develop through five morphologically distinct stages (I to V) and require 10-12 days to fully mature into stage V gametocytes ([@B17], [@B2], [@B3]). Seven days after the onset of clinical symptoms, only mature stage V gametocytes can be identified in the peripheral blood circulation of an infected patient and these gametocytes can persist for weeks in the circulating blood ([@B29]). Immature or early stage gametocytes (stages I to III) are often sensitive to shizonticidal drugs ([@B28], [@B9], [@B10]) and circulating mature stage V gametocytes are sensitive to doses of primaquine (PQ) as low as 0.25 mg/kg ([@B37]). On the contrary, *Plasmodium vivax* gametocytes are present at the beginning of the infection, but only live in the blood for a few days ([@B3]). These biological differences between *P. falciparum* and *P. vivax* gametocytes suggest that the latter is more likely to maintain transmission to the vector before a proper diagnosis and treatment. Once chloroquine (CQ) or any other artemisinin-based combination therapy (ACT) is initiated, gametocytes ([@B11]) and young trophozoites that are committed to gametocytogenesis are killed ([@B20]). Therefore, the discovery of *P. vivax* anti-gametocytocidal drugs has not been a priority in malaria control and elimination efforts. However, any therapeutic strategy that intends to kill *P. vivax* gametocytes before treatment is initiated represents an innovative method of controlling *P. vivax* transmission.

In 2000, the United Nations established the Millennium Declaration, which aimed to halt and then reverse "the scourge of malaria" by 2015 ([@B35]). In 2007, the WHO published a manual with guidelines for malaria elimination ([@B36]), creating renewed attention and interest in the field. Since the manual's publication, the major achievements and failures of the Italian Malaria Eradication Campaign from the 1950s have been reconsidered. Many innovative strategies during the Italian campaign, including DDT spraying, focused on vector control ([@B18]), but the addition of antimalarials to daily consumed food received special attention. At the beginning of the 1950s, Mário Pinotti, a Brazilian pharmacist and physician, proposed the addition of CQ to food salt as a novel chemoprophylaxis against malaria ([@B21]). While pyrimethamine was initially used, CQ was eventually selected because of pyrimethamine's high toxicity. At that time, both *P. falciparum* and *P. vivax* were sensitive to CQ, which is safe for human consumption ([@B7]). On other continents, successful trials using a weekly dose of CQ supported the proposed strategy ([@B6], [@B13], [@B15], [@B19]). During the same decade, similar experiments were successfully conducted in hospitals and in field conditions in Brazil ([@B22], [@B23], [@B24], [@B26], [@B30], [@B25]). A major problem with CQ-enriched salt was precipitation under conditions of high humidity and temperatures in the endemic areas, which left most of the active compound at the bottom of the packages. As a result of its strong bitterness, many people discarded the supplemented salt before a sufficient amount of the drug was consumed (PL Tauil, unpublished observations); insufficient consumption of drugs is a known risk factor for the development of drug resistance. For this reason, after the first trial, Pinotti was concerned about the possibility of antimalarial resistance, which manifested years later in *P. falciparum*(da [@B8]). This result was crucial for abandoning this strategy. More recently, *P. vivax* has also developed resistance to CQ in the Amazon ([@B1], [@B27]).

Currently, strategies such as MDA with low doses of PQ are a realistic tool for eliminating malaria in areas where *P. falciparum* is a major problem. However, even in areas where malaria control is effective, *P. vivax* becomes a major problem because of frequent relapses and insufficient attention to the potential gametocyte carriers. Therefore, the development of a drug that kills *P. vivax* gametocytes before the beginning of treatment could be a useful tool in controlling the transmission of this parasite. An innovative approach for malaria elimination would be the reintroduction of chemoprophylaxis by enriching food salt with a drug that is active exclusively against gametocytes, thereby avoiding the selection of resistant asexual stages against routinely used antimalarials. For a chemoprophylactic strategy, the ideal drug should be (i) efficacious exclusively against gametocytes (to avoid cross-resistance with asexual stages), (ii) non-toxic to humans at the recommended dosages, (iii) stable under environmental and cooking temperatures, (iv) capable of maintaining the original organoleptic characteristics of the food and (v) safe in glucose-6-phosphate dehydrogenase (G6PD)-deficient populations.

PQ is currently available at low doses and tafenoquine, a new 8-aminoquinoline drug that is derived from PQ, and has a prolonged half-life, currently undergoing Phase III trials as an antirelapse drug ([@B16]). These drugs are viable options for a chemoprophylactic strategy, however not safe for G6PD-deficient populations.

The identification of potential inhibitors of *P. falciparum*transmission has increased in recent years due to improvement in culture techniques. To catalyse the development of new antimalarials, Medicines for Malaria Venture (MMV) and SCYNEXIS assembled the Malaria Box ([@B31]), an open access library of 400 compounds. The compounds were originally identified from phenotypic screening against *P. falciparum*asexual stages using over four million compounds from the research libraries of Saint Jude Children's Research Hospital, Novartis and GlaxoSmithKline ([@B14]). Laboratories around the world have taken the lead by testing these compounds against the late stages of *P. falciparum*gametocytes ([@B12], [@B4], [@B32]). Compounds that appear to be specific against gametocytes have been identified and these compounds can potentially serve as starting points for the development of inhibitors that exclusively kill gametocytes. However, the selection of hit-to-lead compounds from multistage approaches is typically based on activity against both asexual and sexual stages, thereby providing less attention to agents that are only active against gametocytes. Although further investigation is required to discover more suitable leads for the proposed chemoprophylactic strategy, the concept itself may reopen an avenue to aid malaria elimination efforts*.* These efforts may also include drugs that have a newly recognised action against malaria vectors, such as ivermectin, the safety of which was confirmed by the administration of millions of doses in MDA efforts for other neglected diseases ([@B5]).
